Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma | Zendy

Klaus F. Rabe | Zendy; Parameswaran Nair | Zendy; Guy Brusselle | Zendy; Jorge Máspero | Zendy; Mario Castro | Zendy; Lawrence Sher | Zendy; Hongjie Zhu | Zendy; Jennifer D. Hamilton | Zendy; Brian N. Swanson | Zendy; Asif Khan | Zendy; Jingdong Chao | Zendy; Heribert Staudinger | Zendy; Gianluca Pirozzi | Zendy; Christian Antoni | Zendy; Nikhil Amin | Zendy; Marcella Ruddy | Zendy; Bolanle Akinlade | Zendy; Neil M.H. Graham | Zendy; Neil Stahl | Zendy; George D. Yancopoulos | Zendy; Ariel Teper | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma

Author(s) -

Klaus F. Rabe,

Parameswaran Nair,

Guy Brusselle,

Jorge Máspero,

Mario Castro,

Lawrence Sher,

Hongjie Zhu,

Jennifer D. Hamilton,

Brian N. Swanson,

Asif Khan,

Jingdong Chao,

Heribert Staudinger,

Gianluca Pirozzi,

Christian Antoni,

Nikhil Amin,

Marcella Ruddy,

Bolanle Akinlade,

Neil M.H. Graham,

Neil Stahl,

George D. Yancopoulos,

Ariel Teper

Publication year - 2018

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1804093

Subject(s) - dupilumab , asthma , glucocorticoid , medicine , rescue therapy , dermatology , immunology

Dupilumab is a fully human anti-interleukin-4 receptor α monoclonal antibody that blocks both interleukin-4 and interleukin-13 signaling. Its effectiveness in reducing oral glucocorticoid use in patients with severe asthma while maintaining asthma control is unknown.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research